Figure 1.

Systemic administration of DX109 inhibited macrophage activation and suppressed EAU. B10.RIII mice were used by Copland et al5 to test the efficacy of DX109 in their EAU model of autoimmune disease due to their increased susceptibility to autoimmune disease. Immunization of B10.RIII mice with hRBP-3 peptide led to the proliferation of CD4⁺ autoimmune T cells, macrophage activation, and EAU induction (left). In contrast, B10.RIII mice treated with DX109 displayed reduced signs of disease and fewer infiltrating macrophages (right). Furthermore, interferon (IFN)-γ-treated macrophages incubated with DX109 showed reduced levels of the proinflammatory cytokine interleukin (IL)-6 as well as nitric oxide, as compared with controls.